GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Karolinska Development AB (STU:2I9) » Definitions » EV-to-Revenue

Karolinska Development AB (STU:2I9) EV-to-Revenue : 185.89 (As of May. 17, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Karolinska Development AB EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Karolinska Development AB's enterprise value is €31.60 Mil. Karolinska Development AB's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was €0.17 Mil. Therefore, Karolinska Development AB's EV-to-Revenue for today is 185.89.

The historical rank and industry rank for Karolinska Development AB's EV-to-Revenue or its related term are showing as below:

STU:2I9' s EV-to-Revenue Range Over the Past 10 Years
Min: 74.49   Med: 162.5   Max: 576.94
Current: 190.81

During the past 13 years, the highest EV-to-Revenue of Karolinska Development AB was 576.94. The lowest was 74.49. And the median was 162.50.

STU:2I9's EV-to-Revenue is ranked worse than
88.02% of 1043 companies
in the Biotechnology industry
Industry Median: 8.03 vs STU:2I9: 190.81

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-17), Karolinska Development AB's stock price is €0.1262. Karolinska Development AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was €0.00. Therefore, Karolinska Development AB's PS Ratio for today is .


Karolinska Development AB EV-to-Revenue Historical Data

The historical data trend for Karolinska Development AB's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Karolinska Development AB EV-to-Revenue Chart

Karolinska Development AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 175.88 103.84 445.24 113.81 181.52

Karolinska Development AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 133.21 138.85 143.53 181.52 176.72

Competitive Comparison of Karolinska Development AB's EV-to-Revenue

For the Biotechnology subindustry, Karolinska Development AB's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Karolinska Development AB's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Karolinska Development AB's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Karolinska Development AB's EV-to-Revenue falls into.



Karolinska Development AB EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Karolinska Development AB's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=31.601/0.17
=185.89

Karolinska Development AB's current Enterprise Value is €31.60 Mil.
Karolinska Development AB's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.17 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Karolinska Development AB  (STU:2I9) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Karolinska Development AB's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.1262/0
=

Karolinska Development AB's share price for today is €0.1262.
Karolinska Development AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Karolinska Development AB EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Karolinska Development AB's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Karolinska Development AB (STU:2I9) Business Description

Traded in Other Exchanges
Address
TomtebodavAgen 23 A, Solna, SWE, SE-171 65
Karolinska Development AB is a life science investment company. It is focused on identifying breakthrough medical innovations in the Nordic region. It selects commercially attractive medical innovations, develops innovations to the stage where the return on investment can be achieved and commercializes the innovations through the sale of companies or out-licensing of products. The company focused on profiles namely Aprea Therapeutics; Modus Therapeutics; BioArctic; Umecrine Cognition; and OssDsign.

Karolinska Development AB (STU:2I9) Headlines

No Headlines